Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOZANTINIB S-MALATE Cause Device occlusion? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Device occlusion have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 0.0% of all adverse event reports for CABOZANTINIB S-MALATE.

7
Reports of Device occlusion with CABOZANTINIB S-MALATE
0.0%
of all CABOZANTINIB S-MALATE reports
3
Deaths
5
Hospitalizations

How Dangerous Is Device occlusion From CABOZANTINIB S-MALATE?

Of the 7 reports, 3 (42.9%) resulted in death, 5 (71.4%) required hospitalization.

Is Device occlusion Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABOZANTINIB S-MALATE. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does CABOZANTINIB S-MALATE Cause?

Diarrhoea (8,282) Fatigue (6,819) Off label use (5,245) Nausea (4,341) Decreased appetite (4,076) Blood pressure increased (2,939) Malignant neoplasm progression (2,718) Palmar-plantar erythrodysaesthesia syndrome (2,706) Weight decreased (2,657) Stomatitis (2,560)

What Other Drugs Cause Device occlusion?

PEGFILGRASTIM (3,239) CARBIDOPA\LEVODOPA (1,464) SOMATROPIN (823) LEUPROLIDE (786) EPOPROSTENOL (580) TREPROSTINIL (458) ALBUTEROL (431) MEDROXYPROGESTERONE (284) BACLOFEN (254) LEVODOPA (224)

Which CABOZANTINIB S-MALATE Alternatives Have Lower Device occlusion Risk?

CABOZANTINIB S-MALATE vs CAFFEINE CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL CABOZANTINIB S-MALATE vs CALCIFEDIOL CABOZANTINIB S-MALATE vs CALCIPOTRIENE

Related Pages

CABOZANTINIB S-MALATE Full Profile All Device occlusion Reports All Drugs Causing Device occlusion CABOZANTINIB S-MALATE Demographics